Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.
Advanced Gastric Cancer
DRUG: Apatinib and PD1
Overall survival rate, up to 2 year
Objective response rate, Defined as the proportion of patients with a documented complete response, and partial response (CR

+ PR, up to 2 year|Disease control rate, The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason, up to 2 year|Overall survival, From date of randomization until the date of death from any cause, up to 2 year
Patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.